Living Medicine Articles & Analysis
6 news found
BlueRock Therapeutics, a clinical stage biopharmaceutical company and wholly-owned subsidiary of Bayer?AG, announced?today?that Emile Nuwaysir, Ph.D., current President and CEO, will transition to the position of BlueRock Board Chair, effective August 1, 2021. Current Chief Scientific Officer Seth Ettenberg, Ph.D., will assume the role of President and CEO. BlueRock will continue in its mission ...
” “I’m excited to work with Brendan and the team to deliver on the promise of our platform and bring new medicines to patients,” said Kay. “I’ve been wondering about what AI means for drug development for some time; there’s a lot of talk out there that sounds like magic. ...
Redbiotec AG has entered into a research collaboration and exclusive option agreement with a large-cap pharmaceutical company. The collaboration will leverage Redbiotec’s proprietary bacteria platform BRISPR® for the targeted delivery of gene therapy cargos from the partner. “Redbiotec’s bacteria hold great potential in overcoming the delivery hurdles faced by conventional ...
Redbiotec AG, a pioneer in living medicines, further expands its Scientific Advisory Board with the appointment of Professor Michele Calos, PhD. ...
Redbiotec AG, a pioneer in living medicines, is pleased to announce the addition of Professor Christoph U. ...
Both the U.S. and China are committed to policies and investment that accelerate the adoption of precision medicine globally. In China, precision medicine is a prominent part of the 13th Five-Year Plan, which sets an ambitious roadmap and budget. The Summit, "Transforming Lives through Pioneering Precision Medicine," featured ...